George A. Eldridge
Known title: SEE REMARKSCIK: 0001413006
Associated companies
Transaction History
| JBIO | ▲ Buy | Option Exercise | 15,000 | $32K | 6/14/2024 | View on chart |
| JBIO | ▼ Sell | Open Market | 15,000 | $375K | 6/14/2024 | View on chart |
| JBIO | ▼ Sell | Open Market | 771 | $21K | 4/10/2024 | View on chart |
| JBIO | ▲ Buy | Option Exercise | 7,500 | $16K | 4/10/2024 | View on chart |
| JBIO | ▼ Sell | Open Market | 6,729 | $180K | 4/10/2024 | View on chart |
| JBIO | ▲ Buy | Option Exercise | 12,495 | $27K | 4/1/2024 | View on chart |
| JBIO | ▼ Sell | Open Market | 12,495 | $390K | 4/1/2024 | View on chart |
| JBIO | ▲ Buy | Option Exercise | 2,016 | $4K | 3/13/2024 | View on chart |
| JBIO | ▼ Sell | Open Market | 2,016 | $50K | 3/13/2024 | View on chart |
| JBIO | ▲ Buy | Option Exercise | 2,051 | $4K | 3/12/2024 | View on chart |
| JBIO | ▼ Sell | Open Market | 2,051 | $51K | 3/12/2024 | View on chart |
| JBIO | ▼ Sell | Open Market | 3,423 | $86K | 3/11/2024 | View on chart |
| JBIO | ▼ Sell | Open Market | 10 | $263 | 3/11/2024 | View on chart |
| JBIO | ▲ Buy | Option Exercise | 3,433 | $7K | 3/11/2024 | View on chart |
| JBIO | ▲ Buy | Option Exercise | 114 | $244 | 3/8/2024 | View on chart |
| JBIO | ▼ Sell | Open Market | 114 | $3K | 3/8/2024 | View on chart |
| JBIO | ▲ Buy | Option Exercise | 22,386 | $48K | 3/7/2024 | View on chart |
| JBIO | ▼ Sell | Open Market | 22,386 | $560K | 3/7/2024 | View on chart |
| JBIO | ▲ Buy | Option Exercise | 10,000 | $21K | 12/12/2022 | View on chart |
| JBIO | ▼ Sell | Open Market | 10,000 | $300K | 12/12/2022 | View on chart |
| JBIO | ▲ Buy | Option Exercise | 3,969 | $8K | 12/9/2022 | View on chart |
| JBIO | ▼ Sell | Open Market | 3,386 | $82K | 12/9/2022 | View on chart |
| JBIO | ▼ Sell | Open Market | 583 | $15K | 12/9/2022 | View on chart |
| JBIO | ▲ Buy | Option Exercise | 12,011 | $26K | 12/8/2022 | View on chart |
| JBIO | ▼ Sell | Open Market | 20 | $412 | 12/8/2022 | View on chart |
| JBIO | ▼ Sell | Open Market | 960 | $19K | 12/8/2022 | View on chart |
| JBIO | ▼ Sell | Open Market | 11,031 | $267K | 12/8/2022 | View on chart |
| JBIO | ▼ Sell | Open Market | 4,558 | $93K | 12/7/2022 | View on chart |
| JBIO | ▼ Sell | Open Market | 7,079 | $137K | 12/7/2022 | View on chart |
| JBIO | ▲ Buy | Option Exercise | 11,637 | $25K | 12/7/2022 | View on chart |
| JBIO | ▲ Buy | Option Exercise | 85 | $182 | 11/30/2022 | View on chart |
| JBIO | ▼ Sell | Open Market | 85 | $2K | 11/30/2022 | View on chart |
| JBIO | ▼ Sell | Open Market | 1,261 | $24K | 11/23/2022 | View on chart |
| JBIO | ▲ Buy | Option Exercise | 1,261 | $3K | 11/23/2022 | View on chart |
| JBIO | ▲ Buy | Option Exercise | 174 | $372 | 11/22/2022 | View on chart |
| JBIO | ▼ Sell | Open Market | 174 | $3K | 11/22/2022 | View on chart |
| JBIO | ▲ Buy | Option Exercise | 2 | $4 | 11/21/2022 | View on chart |
| JBIO | ▼ Sell | Open Market | 2 | $38 | 11/21/2022 | View on chart |
| JBIO | ▼ Sell | Open Market | 780 | $15K | 11/18/2022 | View on chart |
| JBIO | ▼ Sell | Open Market | 81 | $2K | 11/18/2022 | View on chart |
| JBIO | ▲ Buy | Option Exercise | 861 | $2K | 11/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Jade Biosciences Schedules Conference Participation
Jade Biosciences has announced its participation in upcoming industry conferences. Such events typically provide opportunities for company leadership to engage with institutional investors and discuss business developments. The stock currently trades within its 52-week range, with analysts maintaining price targets significantly above current levels.
Jade Biosciences Schedules Conference Participation. Jade Biosciences has announced its participation in upcoming industry conferences. Such events typically provide opportunities for company leadership to engage with institutional investors and discuss business developments. The stock currently trades within its 52-week range, with analysts maintaining price targets significantly above current levels.